Derms on Drugs

Custom Shots and Drug Cocktails

The Derms question treatment monogamy: a personalized melanoma vaccine joins forces with immunotherapy, while dual therapy takes on refractory HS and AD.

AI Crosses the Prescription Line

In Utah, AI is getting its hands on the prescription pad—starting with topical acne treatment. The Derms grill Nolla’s CEO on the big questions: Who catches the misses, a

The Goldilocks Biologic

Dr. Steve Daveluy makes the case that Cosentyx is the “just right” first biologic for HS—but not every Derm is ready to move past TNFs. Durability, infection risk, IBD, a

Tiny Vesicles, Big Claims

Exosomes may be real science, but the marketing has sprinted miles ahead of the data. The Derms dig into their promise for burns and epidermolysis bullosa—and why that pr

Cuts, Switches, and Eight Extra Hairs

Three papers, three practical questions: Who really needs antibiotics before derm surgery? What comes after an AD drug fails? And does taking oral minoxidil in the mornin

Blood, Sweat, and Hives

Dr. Marc Serota makes the case for targeted lab testing in CSU—but the Derms worry it may open a can of worms. The Chronic Urticaria Index gets a closer look, shotgun all

Paging Dr. Telederm

After 70,000 virtual consults, Dr. Joe English knows what a photo can—and can’t—tell you. He joins the Derms to talk diagnostic curveballs, hospital saves, and bringing d

Tregs, Tape, and Tresses

Three papers, three very different reactions: a Treg-boosting AD drug that may be too clever for its own good, a Steri-Strip trick you can use tomorrow, and Rinvoq alopec

Don’t Wait for the Tunnels

Convince the Derms on Drugs makes its debut with Dr. Christopher Sayed making the case for earlier systemic treatment in HS. Can he convince the Derms to act before recur

Patch Me If You Can

Patch first or treat first? The Hamann brothers join the Derms to tackle mystery dermatitis, questionable allergens, wet wraps, hand eczema—and why the answer may be hidi

The Clot Thickens

Three papers, three plot twists: new HS data that underwhelm on paper, a transected melanoma that may not need a sentinel node, and a possible explanation for why JAK clo

The Long and Short of Male Genital Disease

Male genital disease expert Dr. Christopher Bunker joins the Derms for the penis episode no one else was brave enough to make. Lichen sclerosus, circumcision, penile canc

Three Sheets to Tofa

The Derms debut a shorter format with three papers and one newly dirt-cheap drug: generic tofacitinib. The safety, the risks, and the practicalities—right down to getting

Creams, Screams, and Measles

Pediatric dermatology legend Dr. Sheila Fallon Friedlander joins the Derms to sort through the new topical “Goldilocks” problem, take the sting out of Dupixent injections

Can We Stop Referring CSU?

The CSU rulebook is getting a rewrite, and the Derms on Drugs crew has thoughts. Dr. Jason Hawkes joins the conversation to talk new guidelines, new therapies, and why it

The Gray Zone Strikes Again

This week, the DoD tackle studies that leave plenty of room for debate—from skin cancer treatment costs and melanoma risk to HS, alopecia areata, and the real-world decis

Making Nails Sexy Again

The DOD tackle longitudinal melanonychia, retronychia, nail biopsies, and other everyday nail problems—with enough practical pearls to make you rethink your next nail pat

Clinical Controversies: Screening, Patch Testing & Physician Burnout

One paper questions melanoma screening. Another challenges patch testing. By the end, the conversation has wandered into studies on physician burnout and more, sparking e

What If the Biopsy Picked the Biologic?

Dermatologist William Damsky, MD, joins the DoD crew to explore immune biomarkers, treatment prediction, and whether precision dermatology is finally ready for prime time

Don't Blame the Canary

Burnout isn't just about long hours. From moral distress to prior authorizations and system barriers, this week's conversation with Dr. Lisa Swanson explores what's reall